The regulatory environment is fast changing fuelled by digital transformation, and AI-driven tools integration. In this volatile situation, in addition to focusing on developing innovative therapies and life-saving drugs, being agile in decoding ever-changing global regulatory frameworks could be challenging for pharma and MedTech manufacturers. Large pharma manufacturers majorly outsource their regulatory operations to experts outside the organizations. Despite the critical importance of regulatory compliance and the threat to data safety, they do opt for external regulatory service providers due to several strategic and operational reasons.
At Vigilare, with up-to-date intelligence on global and local regulatory requirements, we streamline regulatory operations from strategy design to submission process with extended support for post-approval product lifecycle management. It helps organizations to stay ahead in complex Regulatory environments, mitigate risks, and prepare for compliant regulatory submissions, confident health authority interactions and reduce overall time-to-market. ​
With specialized teams spread across 100+ countries, Vigilare’s regulatory affairs consultants decode  local regulatory requirements and strategically leverage them for a global market entry approach. We monitor regulatory changes across global health authorities (US FDA, EMA, TGA, MHRA, CDSCO, etc.,) and provide actionable insights with a strategic foresight. We assist Life Sciences and MedTech organizations navigate the complex Regulatory landscape with Market Intelligence across geographies, Product Classification & Assessment, Product Registration Norms, Legal Compliance,
Regulatory Landscape Assessment, Government Affairs, Regulatory and Clinical Documentation,
Launch Strategy, and Cost-effectiveness Analysis.
Adoption of eCTD 4.0 to integrate AI methodologies, real world evidence, data security, etc., regulatory submission templates are rapidly evolving. Amidst, preparing your dossier with utmost clarity, and consistency for streamlined review can be challenging without real-time knowledge of the updated templates. At Vigilare, with accurate insights on the submission guidelines and templates, our regulatory affairs consultants align your submission documents, CTD/eCTD, 510(k) or PMA, etc. irrespective of the industry – Pharmaceuticals, Biologics, and/or Medical Devices.Â
At Vigilare, we conduct in-depth gap analysis on current processes, policies, and documentation against those regulatory requirements mandated by global health authorities. Vigilare’s regulatory affairs consultants identify deficiencies and discrepancies to reduce the risk of non-compliance. We also identify, and evaluate the potential operational and procedural risks from the gaps found and mitigate them on time for successful product compliance and timely market access.
Global health authorities are mandating and adopting the zero-tolerance approach to misinformation. It means organizations must ensure that every aspect of the product communication is accurate and must protect patient safety as per the health authority standards to avoid expensive enforcement actions. Vigilare’s regulatory affairs consultants ensure labeling, claims, and advertising materials are compliant starting from compilation to review.
Throughout a product’s development and approval life cycle, there are many times that Life Sciences/MedTech organizations and regulatory agencies interact with each other referring to data clarifications, concern addressals, etc. These could be Pre-IND, End-of-Phase, Pre-NDA/BLA, and Advisory meetings. Vigilare’s regulatory affairs consultants lead the HA meetings, assisting organizations with strategic planning, regulatory guidance, data dissemination, and preparatory or brief sessions.
The EU Medical Device Regulation (MDR 2017/745) replaced the previous MDD and AIMDD, significantly raising requirements for clinical evidence, post-market surveillance, and device traceability. Key impacts include stricter clinical evaluation standards, mandatory Unique Device Identification (UDI) implementation, enhanced post-market clinical follow-up requirements, and the need for re-registration of legacy devices. Non-compliance means devices cannot be sold in Europe. Regulatory affairs consultants help companies close compliance gaps, prepare Technical Documentation, and engage with Notified Bodies.
The FDA target review time for a standard 510(k) submission is 90 FDA days, not calendar days. However, total calendar time from submission to clearance often ranges from 6 to 12 months when accounting for FDA review holds, additional information requests, and back-and-forth correspondence. A well-prepared, complete submission with a strong predicate argument significantly reduces the likelihood of additional information requests. Regulatory consultants who specialize in 510(k) submissions can cut response times and improve first-cycle clearance rates.
Yes. Regulatory requirements differ significantly across markets. The FDA, EMA, MHRA, PMDA (Japan), TGA (Australia), and NMPA (China) each have distinct submission formats, clinical data requirements, labeling standards, and approval timelines. A global regulatory strategy developed early can identify opportunities to leverage data across markets and sequence submissions efficiently. Life sciences regulatory consultants with multi-jurisdictional expertise can develop harmonized strategies that minimize redundancy while meeting each agency specific requirements.
An In Vitro Diagnostic (IVD) is a medical device used to perform tests on specimens taken from the human body, such as blood tests, genetic tests, or COVID-19 tests. Most IVDs intended for commercial use in the US require FDA review through 510(k) clearance, De Novo classification, or PMA approval depending on risk class. Laboratory-developed tests face evolving FDA oversight under a final rule issued in 2024. Regulatory affairs consultants help IVD companies determine the correct regulatory pathway and prepare compliant premarket submissions.